ES2140670T3 - Cicatrizacion de heridas. - Google Patents

Cicatrizacion de heridas.

Info

Publication number
ES2140670T3
ES2140670T3 ES95913237T ES95913237T ES2140670T3 ES 2140670 T3 ES2140670 T3 ES 2140670T3 ES 95913237 T ES95913237 T ES 95913237T ES 95913237 T ES95913237 T ES 95913237T ES 2140670 T3 ES2140670 T3 ES 2140670T3
Authority
ES
Spain
Prior art keywords
wound healing
beta
growth factor
agent
tgf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95913237T
Other languages
English (en)
Inventor
Mark W J Ferguson
Mamta Shah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Victoria University of Manchester
University of Manchester
Original Assignee
Victoria University of Manchester
University of Manchester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9406154A external-priority patent/GB2288118A/en
Priority claimed from GBGB9424898.6A external-priority patent/GB9424898D0/en
Application filed by Victoria University of Manchester, University of Manchester filed Critical Victoria University of Manchester
Application granted granted Critical
Publication of ES2140670T3 publication Critical patent/ES2140670T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

COMPUESTOS QUE FACILITAN LA CURACION DE HERIDAS O TRASTORNOS FIBROTICOS Y QUE INCLUYEN AL MENOS UN AGENTE ESPECIFICO PARA ESTIMULAR AL FACTOR DE CRECIMIENTO O A UNA PROTEINA ASOCIADA A ESTE EN UN SISTEMA Y QUE AFECTA A LA CANTIDAD DE CRECIMIENTO ACTIVO EN EL SISTEMA, EN COMBINACION CON UN VEHICULO FARMACEUTICO ACEPTABLE, UN DILUYENTE O EXCIPIENTE.
ES95913237T 1994-03-29 1995-03-29 Cicatrizacion de heridas. Expired - Lifetime ES2140670T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9406154A GB2288118A (en) 1994-03-29 1994-03-29 Wound healing composition
GBGB9424898.6A GB9424898D0 (en) 1994-12-09 1994-12-09 Wound healing

Publications (1)

Publication Number Publication Date
ES2140670T3 true ES2140670T3 (es) 2000-03-01

Family

ID=26304595

Family Applications (2)

Application Number Title Priority Date Filing Date
ES95913237T Expired - Lifetime ES2140670T3 (es) 1994-03-29 1995-03-29 Cicatrizacion de heridas.
ES99201184T Expired - Lifetime ES2329531T3 (es) 1994-03-29 1995-03-29 Curacion de heridas o de trastornos fibrosos utilizando al menos un agente contra un factor de crecimiento.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES99201184T Expired - Lifetime ES2329531T3 (es) 1994-03-29 1995-03-29 Curacion de heridas o de trastornos fibrosos utilizando al menos un agente contra un factor de crecimiento.

Country Status (12)

Country Link
US (1) US5972335A (es)
EP (2) EP0754058B1 (es)
JP (1) JP4083794B2 (es)
AT (2) ATE186220T1 (es)
AU (1) AU710153B2 (es)
CA (1) CA2186269C (es)
DE (2) DE69535976D1 (es)
DK (2) DK0968723T3 (es)
ES (2) ES2140670T3 (es)
GR (1) GR3032266T3 (es)
NZ (1) NZ282856A (es)
WO (1) WO1995026203A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9106678D0 (en) * 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing
GB2304047A (en) * 1995-08-09 1997-03-12 Univ Manchester Pharmaceutical compositions containing cytokines
GB9601081D0 (en) * 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
GB2306481A (en) * 1995-10-21 1997-05-07 Univ Manchester Pharmaceutical comprising a stimulator of activin and/or inhibin
GB9702943D0 (en) 1997-02-13 1997-04-02 Univ Manchester Wound healing
DE10022074A1 (de) * 2000-05-06 2001-11-08 Henkel Kgaa Elektrochemisch erzeugte Schichten zum Korrosionsschutz oder als Haftgrund
US6509318B1 (en) * 2000-09-29 2003-01-21 The Regents Of The University Of California TGF-B inhibitors and methods
US7569132B2 (en) * 2001-10-02 2009-08-04 Henkel Kgaa Process for anodically coating an aluminum substrate with ceramic oxides prior to polytetrafluoroethylene or silicone coating
US7452454B2 (en) * 2001-10-02 2008-11-18 Henkel Kgaa Anodized coating over aluminum and aluminum alloy coated substrates
GB0217136D0 (en) * 2002-07-24 2002-09-04 Renovo Ltd Wound healing & treatment of fibrosis
US20050074453A1 (en) * 2003-10-02 2005-04-07 Ferree Bret A. Methods of preventing adhesions following laminectomies and other surgical procedures
WO2005097832A2 (en) 2004-03-31 2005-10-20 Genentech, Inc. Humanized anti-tgf-beta antibodies
EP2498798A4 (en) * 2009-11-10 2014-01-01 Univ Columbia COMPOSITIONS AND METHODS OF WOUND TREATMENT
WO2011109808A1 (en) * 2010-03-05 2011-09-09 Wake Forest University Health Sciences Controlled delivery system
CA2845266C (en) 2011-08-17 2020-07-21 Keranetics Llc Methods for extracting keratin proteins
CA2845267C (en) 2011-08-17 2021-07-06 Keranetics Llc Low protein percentage gelling compositions
WO2014074532A2 (en) * 2012-11-06 2014-05-15 Scholar Rock Inc. Compositions and methods for modulating cell signaling
US9827245B2 (en) 2013-03-15 2017-11-28 KeraNetics, LLC Keratin compositions comprising halofuginone
AU2014262843B2 (en) 2013-05-06 2017-06-22 Scholar Rock, Inc. Compositions and methods for growth factor modulation
JP7359547B2 (ja) 2016-05-17 2023-10-11 ジェネンテック， インコーポレイテッド 免疫療法における診断及び使用のための間質遺伝子シグネチャー
MX2020004567A (es) 2017-11-06 2020-08-13 Genentech Inc Metodos diagnosticos y terapeuticos para el cancer.
WO2023080900A1 (en) 2021-11-05 2023-05-11 Genentech, Inc. Methods and compositions for classifying and treating kidney cancer
WO2024077095A1 (en) 2022-10-05 2024-04-11 Genentech, Inc. Methods and compositions for classifying and treating bladder cancer
WO2024077166A1 (en) 2022-10-05 2024-04-11 Genentech, Inc. Methods and compositions for classifying and treating lung cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007057A1 (en) * 1987-03-13 1988-09-22 Amgen Inc. Purified platelet-derived growth factor and methods for purification thereof
US5094941A (en) * 1987-12-31 1992-03-10 Zymogenetics, Inc. Monoclonal antibodies to PDGF
JPH0780780B2 (ja) * 1989-09-29 1995-08-30 ラ ホヤ キャンサー リサーチ ファウンデーション 細胞外マトリックスの蓄積防止のためのトランスフォーミング増殖因子βの阻害
GB9106678D0 (en) * 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing
CA2124591A1 (en) * 1991-12-04 1993-06-10 Erkki I. Ruoslahti Inhibiting transforming growth factor .beta. to prevent accumulation of extracellular matrix
GB9206861D0 (en) * 1992-03-28 1992-05-13 Univ Manchester Wound healing and treatment of fibrotic disorders
WO1993019783A1 (en) * 1992-04-01 1993-10-14 The Whittier Institute For Diabetes And Endocrinology Methods of inhibiting or enhancing scar formation in the cns
GB9217206D0 (en) 1992-08-13 1992-09-23 Pointer John C Photo labels
WO1994009812A1 (en) * 1992-10-26 1994-05-11 Kirin Brewery Company, Limited METHOD FOR PRODUCING LARGE LATENT TRANSFORMING GROWTH FACTOR-β COMPLEXES AND LARGE LATENCY ASSOCIATED PEPTIDE
JP4350370B2 (ja) * 2002-12-27 2009-10-21 株式会社半導体エネルギー研究所 電子回路及び電子機器

Also Published As

Publication number Publication date
JP4083794B2 (ja) 2008-04-30
ES2329531T3 (es) 2009-11-26
CA2186269A1 (en) 1995-10-05
EP0968723B1 (en) 2009-07-01
WO1995026203A1 (en) 1995-10-05
DE69513158D1 (de) 1999-12-09
JPH09510967A (ja) 1997-11-04
CA2186269C (en) 2008-06-03
DK0968723T3 (da) 2009-11-09
ATE186220T1 (de) 1999-11-15
EP0754058B1 (en) 1999-11-03
NZ282856A (en) 1998-06-26
DE69535976D1 (de) 2009-08-13
GR3032266T3 (en) 2000-04-27
DE69513158T2 (de) 2000-05-04
EP0968723A1 (en) 2000-01-05
DK0754058T3 (da) 2000-02-07
AU710153B2 (en) 1999-09-16
EP0754058A1 (en) 1997-01-22
AU2077895A (en) 1995-10-17
ATE435030T1 (de) 2009-07-15
US5972335A (en) 1999-10-26

Similar Documents

Publication Publication Date Title
ES2140670T3 (es) Cicatrizacion de heridas.
DE69530926D1 (de) Mittel zur förderung des haarwachstums
BR9906477A (pt) Cicatrizante de feridas enriquecido com plaquetas aperfeiçoado
ATE247483T1 (de) Matrixprotein enthaltende zusammensetzungen für entzündliche und infektiöse zustände
EE03741B1 (et) N-propargüül-1-aminoindaani R-enantiomeeri, sellesoolade ja kompositsioonide kasutamine
FI953180A0 (fi) Sokeritaudin komplikaatioiden hoitamiseen tarkoitetut koostumukset
DE69524682D1 (de) Mittel zur Behandlung von Wunden
FI973828A (fi) Yhdisteitä ja koostumuksia aktiivisten aineiden annostelemiseksi
CY1108110T1 (el) Παραγοντες και μεθοδοι για προστασια, θεραπεια και επιδιορθωση συνδετικου ιστου
EP0506658A4 (en) Compositions and method for treating painful, inflammatory or allergic disorders
ATE235245T1 (de) Pharmaceutische komposition
DK1100824T3 (da) Forbindelser med væksthormonfrigivende egenskaber
WO2001030334A3 (en) 6-methoxy-2-naphthylacetic acid prodrugs compositions for treating inflammation
DE69104656D1 (de) Heilende Zusammensetzung zur örtlichen Anwendung.
BR9206300A (pt) Processos e composições de tratamento antimicrobiano
UA15363A (uk) Засіб для лікуваhhя відкритих пошкоджеhь

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 754058

Country of ref document: ES